Wockhardt Ltd

Wockhardt Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Wockhardt Ltd

₹ 168 -0.12%
02 Jun - close price
wockhardt.com BSE: 532300 NSE : WOCKPHARMA
About

Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]

Key Points

Market Position
The Co. is amongst top 3 Indian generic companies in the UK and 6th Largest generic supplier in Ireland in Retail and Hospital channels.
Its Wepox is the leader in Erythropoetin market (market share =21%)and Methylcobalamin Brand is no. 1 with (Methycobal= 26.7% market share) {#https://www.bseindia.com/bseplus/AnnualReport/532300/73832532300.pdf#page=34 #}

Website BSE NSE
  • Market Cap ₹ 2,427 Cr.
  • Current Price ₹ 168
  • High / Low ₹ 283 / 145
  • Stock P/E
  • Book Value ₹ 233
  • Dividend Yield 0.00 %
  • ROCE -0.48 %
  • ROE -8.31 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Stock is trading at 0.72 times its book value
  • Company's working capital requirements have reduced from 79.0 days to 52.7 days

Cons

  • Company has low interest coverage ratio.
  • Promoter holding has decreased over last quarter: -1.05%
  • The company has delivered a poor sales growth of -7.60% over past five years.
  • Company has a low return on equity of 4.21% over last 3 years.
  • Promoters have pledged 65.5% of their holding.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
687 598 714 764 632 860 862 854 655 595 679 699 678
673 1,155 697 706 698 739 765 742 688 611 636 654 675
Operating Profit 13 -557 17 58 -66 121 97 112 -33 -16 43 45 3
OPM % 2% -93% 2% 8% -10% 14% 11% 13% -5% -3% 6% 6% 0%
34 1,336 16 101 8 2 4 2 -169 57 -138 -1 -64
Interest 61 74 61 60 55 64 69 80 86 73 70 83 76
Depreciation 61 56 57 68 65 64 61 62 59 64 65 66 56
Profit before tax -75 649 -85 31 -178 -6 -29 -28 -347 -96 -230 -105 -193
Tax % 191% -17% 104% -4% 40% -10% 228% 107% 10% 22% 10% 3% -23%
Net Profit 69 760 3 32 -107 -7 37 2 -311 -75 -207 -102 -237
EPS in Rs 3.35 52.78 0.25 1.06 -6.46 -0.88 2.36 -0.49 -17.91 -4.65 -13.12 -6.66 -14.44
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
4,350 5,609 4,830 4,482 4,453 4,015 3,937 3,566 2,844 2,708 3,230 2,651
2,996 3,606 3,805 3,772 3,959 4,002 3,935 3,604 2,725 2,771 2,932 2,550
Operating Profit 1,355 2,004 1,026 709 494 13 2 -38 119 -63 298 101
OPM % 31% 36% 21% 16% 11% 0% 0% -1% 4% -2% 9% 4%
-394 187 88 67 66 114 -238 116 133 975 -163 -172
Interest 269 215 83 55 129 225 255 265 276 249 299 302
Depreciation 115 122 140 145 142 149 150 164 224 246 247 251
Profit before tax 577 1,853 891 575 289 -247 -641 -351 -247 417 -411 -624
Tax % 41% 14% 5% 28% 13% 9% -4% 38% 82% -65% 32% 0%
Net Profit 343 1,594 843 413 252 -226 -667 -217 -43 688 -279 -621
EPS in Rs 111.87 58.91 28.30 17.45 -13.62 -42.30 -13.52 -4.81 47.64 -16.94 -38.80
Dividend Payout % 0% 3% 13% 54% 0% -56% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -7%
5 Years: -8%
3 Years: -2%
TTM: -18%
Compounded Profit Growth
10 Years: %
5 Years: 3%
3 Years: %
TTM: -209%
Stock Price CAGR
10 Years: -17%
5 Years: -22%
3 Years: -9%
1 Year: -36%
Return on Equity
10 Years: 3%
5 Years: 1%
3 Years: 4%
Last Year: -8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
816 353 353 354 55 55 55 289 55 55 72 72
Reserves 655 2,351 3,228 3,362 3,720 3,281 2,797 2,619 2,616 3,321 3,777 3,282
3,281 2,070 1,906 2,010 2,677 4,160 3,748 3,141 3,582 2,674 2,198 2,184
2,263 1,547 1,433 1,512 1,622 1,486 1,528 1,998 1,894 1,696 2,168 2,145
Total Liabilities 6,254 6,023 6,622 6,939 8,074 8,982 8,128 7,813 8,148 7,746 8,215 7,683
2,571 1,990 2,295 2,123 2,809 2,773 2,888 3,058 3,502 3,343 3,462 4,167
CWIP 902 491 708 1,007 1,036 1,244 1,433 1,445 1,585 1,379 1,342 414
Investments 91 3 577 341 0 563 214 0 0 0 0 0
2,689 3,539 3,043 3,468 4,228 4,403 3,593 3,309 3,060 3,024 3,411 3,102
Total Assets 6,254 6,023 6,622 6,939 8,074 8,982 8,128 7,813 8,148 7,746 8,215 7,683

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
1,352 1,532 1,476 355 -42 -269 68 183 649 -287 413 153
-305 1,074 -823 -222 -105 -684 635 93 -147 1,471 -204 -125
-827 -2,246 -601 -76 193 1,254 -769 -776 -680 -1,171 -71 -315
Net Cash Flow 220 360 52 57 46 301 -66 -500 -178 13 138 -287

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 64 62 36 60 91 94 89 130 159 124 104 110
Inventory Days 211 221 201 250 249 243 174 183 209 256 222 216
Days Payable 129 132 113 136 144 117 122 187 272 223 265 285
Cash Conversion Cycle 146 151 124 175 196 220 141 126 97 157 60 41
Working Capital Days 13 42 9 43 97 96 -16 7 -47 122 62 53
ROCE % 29% 42% 18% 11% 7% -1% -1% -1% 0% 13% 1% -0%

Shareholding Pattern

Numbers in percentages

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
72.13 72.12 72.12 72.12 69.68 68.04 67.13 67.13 65.75 63.83 60.36 59.31
4.69 4.64 4.07 3.10 2.74 2.88 2.95 2.89 2.82 2.98 2.87 2.78
0.21 0.05 0.05 0.09 0.08 0.05 0.09 0.09 0.09 0.15 0.22 0.22
22.97 23.19 23.75 24.69 27.50 29.02 29.83 29.89 31.34 33.04 36.55 37.70

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls